PRF TECHNOLOGIES LTD

PRFX is the ticker for PainReform Ltd., a clinical-stage pharmaceutical company focused on developing extended-release injectable formulations for post-operative pain management. Its lead product candidate, PRF-110, is designed to deliver a local anesthetic directly into the surgical site to provide prolonged pain relief and potentially reduce reliance on opioids after surgery. As a development-stage company, its progress depends heavily on clinical trial outcomes and regulatory milestones.

PRFX trades on the Nasdaq Capital Market under the ticker symbol PRFX. Nasdaq is a major U.S. electronic exchange where many small-cap and micro-cap companies are listed. Investors can typically buy or sell PRFX through a standard brokerage account that offers U.S. equity trading. For exact listing details and any exchange notices, check the latest PRFX quote page.

Recent performance for PRFX depends on current market trading. The page's latest PRFX quote and chart show the most up-to-date price, daily change, and short-term trend. Clinical-stage biotech stocks like PRFX can be sensitive to trial updates, financing news, and broader market sentiment, so recent performance may reflect those factors. Review the live PRFX data displayed on this page for accurate recent figures.

PRFX is a small-cap, clinical-stage biotech stock, a category often associated with higher volatility than large, diversified companies. Its price can move sharply on clinical trial news, regulatory developments, financing activities, or changes in investor sentiment toward the sector. Liquidity can also amplify price swings. For current volatility measures, such as beta or recent trading ranges, refer to the latest PRFX data shown on this page.

Valuing PRFX is not straightforward because clinical-stage biopharma companies often have little or no product revenue, making traditional metrics like P/E less meaningful. Investors may instead consider cash position, research and development spending, pipeline progress, potential market size, and dilution risk. Analyst estimates and risk-adjusted models are sometimes used. For current valuation-related figures, check the latest PRFX data on this page.

Key risks for PRFX include clinical trial failure or delays, regulatory setbacks, and the need for additional capital, which can dilute existing shareholders. As a small-cap biotech, it also faces competition, limited commercial infrastructure, dependence on key personnel, and potential illiquidity in its shares. Broader market and sector sentiment can further pressure the stock. For a full risk profile, review PRFX's latest filings and the data displayed on this page.